4
Changes in Ownership
Spyre Therapeutics, Inc. Filed Acc 0001636282-26-000026
Chief Executive Officer sold 15,000 shares at an average $42.19 ($632,866)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Turtle Cameron Chief Executive Officer | 2026-03-02 | Sale 10b5-1 | −5,900 | $41.73 | $246,207 | 651,640 | D |
| Turtle Cameron Chief Executive Officer | 2026-03-02 | Sale 10b5-1 | −9,100 | $42.49 | $386,659 | 642,540 | D |
| Open-market sales · 15,000 sh · avg $42.19 · $632,866 | |||||||
Loading xslF345X05/wk-form4_1772591487.xml…